drugset / Trial / NCT06188702
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2
Active not recruiting
60 enrolled
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier · collabTango Therapeutics, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Timeline
- Start
- 2024-04-29
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
Indications
No indication recorded.